Sökning: "methylthioadenosine phosphorylase"

Hittade 3 avhandlingar innehållade orden methylthioadenosine phosphorylase.

  1. 1. Targeting the nucleotide metabolism of the mammalian pathogen Trypanosoma brucei

    Författare :Munender Vodnala; Anders Hofer; Arne Holmgren; Umeå universitet; []
    Nyckelord :NATURVETENSKAP; NATURAL SCIENCES; Trypanosoma brucei; adenosine kinase; thymidine kinase; methylthioadenosine phosphorylase; mouser ribonucleotide reductase; E. coli ribonucleotide reductase; RNR; Ara-A; F-Ara-A; dNTP; NTP; doexynucleotide metabolism; nucleosides; nucleoside kinases; allosteric regulation; biologisk kemi; biological chemistry;

    Sammanfattning : Trypanosoma brucei causes African sleeping sickness in humans and Nagana in cattle. There are no vaccines available against the disease and the current treatment is also not satisfactory because of inefficacy and numerous side effects of the used drugs.T. LÄS MER

  3. 2. Targets and strategies for drug development against human African sleeping sickness

    Författare :Farahnaz Ranjbarian; Anders Hofer; Staffan G. Svärd; Umeå universitet; []
    Nyckelord :NATURVETENSKAP; NATURAL SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; T. brucei thymidine kinase; T. brucei methylthioadenosine phosphorylase; FANA-A purine nucleoside analogues; essential oils;

    Sammanfattning : Trypanosoma brucei is a causative agent of African sleeping sickness. It is an extracellular parasite which circulates in the blood, lymph and eventually invades the central nervous system. LÄS MER

  4. 3. Pharmacokinetic studies on cladribine

    Författare :Synnöve Lindemalm; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : The aims of the present study were to delineate the pharmacokinetics, in plasma and leukaemia cells, of cladribine (M), and to describe factors influencing the outcome of administration of CdA in order to individualize and optimize treatment. CdA is a nucleoside analogue with a cytotoxic activity in low-grade lymphoproliferative disorders and childhood acute myelogenous leukaemia. LÄS MER